首次出版:最新修訂:March 2009交付方式:特快專遞(2-3天送達(dá))
報告屬性:共121頁下載目錄 版權(quán)聲明
定購電話:0755-82571522、82571566、400-008-1522
24小時服務(wù)熱線:138 0270 8576 定制報告
版本 | 在線版 | 電子版+印刷版 | 在線報告庫(超1000份報告)全庫 |
---|---|---|---|
優(yōu)惠價 | RMB 6800 | RMB 7800 | RMB 9800 |
原價 | RMB 9600 | RMB 9800 | - |
聯(lián)系電話: 400 008 0586; 0755-82571568
微信掃碼:
1.EXECUTIVESUMMARY
·ExecutiveSummary
Introduction
2.TOTALMARKETINTRODUCTION
·ResearchScopeandSegmentation
ScopeandSegmentation
ResearchMethodology
·DiseaseOverviewandTreatmentOptions
DiseaseOverview
DiseaseProgression
DiseaseCausesandRiskFactors
DiseaseBurden
Diagnosis
TreatmentOverview
·TotalMarketIntroduction
Introduction
CompetitiveStructure
MarketEngineeringMeasurements
UnmetNeedsintheAlzheimer'sDiseaseMedicationMarket
PatientForecasts
RevenueForecasts
MarketShareAnalysis
·GeneralMarketTrends
IndustryChallenges
MarketDrivers
MarketRestraints
·StrategiesforGrowth
StrategicRecommendations
3.CHOLINESTERASEINHIBITORSMARKET
·MarketOverview
Introduction
MarketEngineeringMeasurements
·ProductAnalysis
FDA-approvedProducts
PipelineAnalysis
·MarketForecasts
AriceptForecast
ExelonForecast
RazadyneForecast
CholinesteraseInhibitorsMarket
MarketShareAnalysis
4.NMDARECEPTORANTAGONISTSMARKET
·MarketOverview
Introduction
MarketEngineeringMeasurements
·ProductAnalysis
Namenda
PipelineAnalysis
·MarketForecasts
NamendaForecast
5.NEWMECHANISMPRODUCTSINDEVELOPMENT
·Overview
Introduction
AmyloidPlaqueInhibitorsPipelineAnalysis
SecretaseInhibitorsPipelineAnalysis
ImmunotherapeuticsPipelineAnalysis
OtherNewMechanismDrugsPipelineAnalysis
·MarketForecasts
AlzhemedForecast
FlurizanForecast
6.APPENDIX
·DecisionSupportDatabase
NumberofAlzheimer'sPatients
Alzheimer'sDiseaseDeaths
TotalHealthcareExpenditure
MalePopulation65andAbove
FemalePopulation65andAbove
The U.S. Alzheimer' s disease medication markets research service provides revenue and patient forecasts, competitive analysis, market trends, product analysis and strategies for growth. The market is segmented by product type into cholinesterase inhibitors, NMDA receptor antagonists and new mechanism drugs. Each of the segments discusses in detail marketed products, revenue forecasts, product pipeline and competitive structure.